Summary: The combination of cyclophosphamide and topotecan (cyclo/topo) has shown objective responses in relapsed Ewing sarcoma, but the response duration is not well documented. We reviewed characteristics and outcome of 14 patients with Ewing sarcoma, treated uniformly at a single institution and offered cyclo/ topo at first relapse. Six patients (43%) had relapse at distant sites. All patients received first-line salvage therapy with cyclophosphamide 250 mg/m 2 and topotecan 0.75 mg/m 2 , daily for 5 days repeated every 21 days. The median number of cycles was 4 (range 1 to 10). All toxicities were manageable, the most common being transient cytopenias. There were also 4 episodes of febrile neutropenia, and 3 episodes of gross hematuria. Response was assessable in 13 patients and showed progressive disease in 6 (46%), stable disease in 4 (31%), and partial response in 3 (23%). Nine patients had local control, consisting of radical surgery in 2, radiation in 3, and a combination in 4 patients. Response, when it occurred, was maintained for a median of 8 months (range, 4 to 28 mo). Four patients (29%) are alive at 3, 7, 9, and 110 months after relapse; 1 is receiving cyclo/topo, 1 is on third-line therapy, and 2 are in second and fourth remission. The low toxicity of this combination, and the lack of sustained responses, warrant its investigation in combination with targeted or novel therapeutic agents in relapsed disease.
(J Pediatr Hematol Oncol 2013;35:356-360) E wing sarcoma is the third most common sarcoma in childhood. 1 With current multimodality therapy, approximately 40% of patients will experience disease recurrence or progression. 2 The outcome of patients with recurrent disease is poor; especially those with disease not amenable to surgical resection or adequate local control. [3] [4] [5] [6] Over the past 10 years, a few new chemotherapeutic agents have been introduced, which have shown efficacy against Ewing sarcoma in phase II clinical trials. The most effective such combination is that of cyclophosphamide and topotecan (cyclo/topo). In a phase II study of patients with recurrent solid tumors, which included 17 patients with Ewing sarcoma, 2 achieved complete response (CR), 4 achieved partial response (PR), and 6 had stable disease (SD), with an overall objective response of 35%. 7 In a therapeutic window study conducted by the Children's Oncology Group in the United States, treatment of patients with Ewing sarcoma with cyclo/topo resulted in PR in 21 of 37 patients, accounting for a response rate of 56%, and 15 more patients had SD. 8 A review of the German experience with this regimen, in patients with Ewing sarcoma who received cyclo/topo at either first or second relapse, showed a response rate of 32.6%. 9 In that study, one third of the patients were alive at a median follow-up of 14.5 months (range, 2.1 to 59.8 mo), of whom a proportion had subsequently received other therapies.
Because of the promising early responses discussed above, we decided to offer this combination as a first-line salvage regimen for patients with first relapse or progression of Ewing sarcoma, to identify the extent and duration of response in this disease. We now report the results of treatment of Ewing sarcoma at first relapse with this combination, at a single institution and in a uniformly treated patient population.
PATIENTS AND METHODS
All patients with first relapse or progression of Ewing sarcoma between January 2002 and December 2011, treated at the American University of Beirut Medical Center (AUBMC), were included. Clinical information was collected retrospectively from the medical records. This study was approved by the AUBMC Institutional Review Board.
First-line treatment of all patients with Ewing Sarcoma treated at the AUBMC after 2003 consisted of cycles of VDC (vincristine 2 mg/m 2 IV push on day 1, doxorubicin 37.5 mg/m 2 /day as continuous infusion over 48 h, and cyclophosphamide 1200 mg/m2/dose over 1 h on day 1), alternating every 21 days with IE (ifosfamide 1800 mg/m 2 /d IV over 1 h for 5 d and etoposide 100 mg/m 2 /day IV over 1 h for 5 d), for a planned total of 14 cycles, as per the National Cancer Institute protocol INT-0091. 10 Before 2003, patients were treated with VDC alone, using the same doses as described above.
Upon documentation of disease relapse or progression, patients underwent staging of disease, and were then offered treatment with combination chemotherapy consisting of cyclophosphamide 250 mg/m 2 /day as an infusion over 30 minutes, followed by topotecan 0.75 mg/m 2 /day over 30 minutes, given daily for 5 days, and repeated every 21 days. Each cycle was followed by G-CSF support, and Mesna was used for uroprotection during and after the cyclophosphamide infusion.
Response was evaluated by radiologic imaging (computed tomography or magnetic resonance imaging) of all sites of disease after 2 cycles of chemotherapy then every 2 to 3 cycles, or earlier if symptoms suggested disease progression. Response was defined as follows: CR was defined as resolution of all evidence of disease; PR as >25% reduction in the sum of the maximum perpendicular diameters of all measurable lesions without appearance of any new lesion or progression in any existing lesion; SD as <25% change in the sum of the maximum perpendicular diameters of all measurable lesions without appearance of any new lesions; and progressive disease as >25% increase in the sum of the maximum perpendicular diameters of any measurable lesion or appearance of any new lesion.
The incidence and pattern of toxicities were reviewed retrospectively, and were graded according to the CTCAE version 4.0 criteria. Survival was defined as the time interval from date of diagnosis of relapse/progression to either death from any cause or last follow-up. Event-free survival was defined as time to further disease progression, relapse, or death from any cause.
RESULTS

Patient Characteristics
Of a total of 41 patients with Ewing sarcoma treated at our institution between January 2002 and December 2011, recurrent disease occurred in 17 patients. Two patients refused further treatment upon relapse, and 1 patient was treated with a non-topotecan-containing regimen. Therefore these 3 patients were not included, and the study included a total of 14 patients.
The patient characteristics are detailed in Table 1 . Median age was 11 years (range, 2 to 19 y). Three patients had not completed the planned first-line therapy for initial disease: 2 because of primary progression of disease while on first-line therapy (patients 1 and 2 in Table 1 ); and the third patient had interruption of his initial treatment after 8 cycles because of active hepatitis C infection, and subsequently returned with disease progression (patient 6 in Table 1 ). Primary tumor site was axial in 11 patients (5 pelvic, 3 chest wall, 1 scapula, 1 clavicle, 1 sinus), and in 1 patient each was located in the axilla, extremity (femur), and multifocal bone. Three patients had initial metastatic disease, and 2 patients with rib lesions had regional extensive disease involving the pleural cavity. During their initial treatment, all but 2 patients had received local control: 1 had undergone complete surgical resection of the tumor, 8 had undergone radiation alone, and 3 had undergone surgical resection as well as radiation therapy because of positive margins. For the 2 patients who did not receive local control, the reasons were primary disease progression in 1 patient before timing of local control (patient #1), and new-onset hepatitis C during therapy in the second patient, so treatment had to be interrupted and local control was not pursued (patient #6).
The patient characteristics at the time of first relapse are detailed in Table 2 . The median time to disease recurrence was 17.5 months (range, 6 to 36 mo). Eight patients had local or regional recurrences; the rest had recurrence at distant sites (2 presented with lung disease, 3 with bone metastases, and 1 with bone marrow disease). Mean time of follow-up after start of salvage therapy was 35 months (median 32 mo; range, 2 to 110 mo).
Therapy
All 14 patients received combination chemotherapy with cyclophosphamide and topotecan. As shown in Table 2 A total of 64 cycles of cyclo/topo chemotherapy were given, with a median number of 4 cycles per patient (range, 1 to 10 cycles per patient). Treatment-related toxicities were manageable, with the most frequently encountered toxicities being primarily limited to mild, transient cytopenia. Treatment was stopped because of either disease progression, or after at least 8 cycles in patients who achieved complete remission; no patient had treatment terminated due to toxicity. Toxicities: Hematologic toxicity was frequent. There were 20 episodes of grade 3-4 thrombocytopenia, which occurred in 5 of the 14 patients (range, 0 to 8 episodes per patient). Grades 3 to 4 anemia occurred in 8 of the 14 patients for a total of 23 episodes (range, 0 to 8 episodes per patient); and grades 3 to 4 neutropenia in 11 of 14 patients, with a total of 31 occurrences (range, 0 to 5 episodes per patient). Despite the frequent cytopenias, there were a total of 4 episodes of febrile neutropenia (grade 3), which were managed by prompt inpatient intravenous antibiotics. Other encountered toxicities were 3 episodes of hemorrhagic cystitis in 2 patients; of note, 1 patient had tumor invading the bladder wall (patient #2), which may have contributed to the hematuria, and he had disease progression after 1 cycle of cyclo/topo. The other patient had 2 episodes of hemorrhagic cystitis (grade 3), and was able to receive subsequent cycles of cyclo/topo. There were no toxic deaths.
Response and Outcome
One patient could not be assessed for response because he underwent upfront complete tumor resection. Thus he was in CR postoperatively, and no measurable disease was present at commencement of adjuvant cyclo/topo chemotherapy. Of the assessable 13 patients, 6 (46%) had disease progression after 1 to 3 cycles, whereas 3 (23%) showed a measurable PR, and 4 (31%) had SD. For the 7 patients who showed PR or SD, the response was maintained for a median of 8 months (range, 4 to 28 mo).
Four of the 14 patients are currently alive: 1 continues to receive cyclo/topo therapy with residual active disease; 1 underwent upfront resection followed by 8 cycles of therapy and is in sustained second CR; 1 experienced disease progression, underwent aggressive resection and is currently on second-line salvage therapy with no active disease; and 1 patient is in sustained fourth complete remission 110 months after initial relapse.
DISCUSSION
The outcome after relapse of Ewing sarcoma continues to be quite poor, 4,5,11 as has been recently confirmed in a large retrospective study. 12 Several chemotherapeutic agents and regimens have shown efficacy in relapsed Ewing sarcoma, including cyclo/topo, 7-9 irinotecan/temozolomide, 13, 14 and high-dose ifosfamide alone, or ifosfamide as part of ICE (ifosfamide, carboplatin, and etoposide). 15, 16 Other agents that have shown promising activity include gemcitabine/docetaxel, 17 ecteinascidin-743, 18, 19 and recently developed targeted agents such as mTOR inhibitors, IGF1R-inhibitors, bevacizumab, and others. 20, 21 The emergence of new agents that have demonstrable efficacy against relapsed Ewing disease now necessitates review of the available combination therapies to decide which are most suitable for further investigation, alone or in combination, to improve salvage rates after recurrence. The fact that patients are treated heterogenously after relapse makes it difficult to draw conclusions about efficacy of a particular regimen, as prior exposure to different chemotherapeutic agents may modulate response to therapy. We therefore performed this study to better define the extent and duration of response to cyclo/topo, at first relapse in a uniformly treated population of patients with Ewing sarcoma.
Our results show that response rates to cyclo/topo at first relapse of Ewing sarcoma are very similar to those reported in a mixed cohort of patients treated at either first or second relapse, 9 and similar to results seen in phase II trials conducted on patients with relapsed or refractory solid tumors. 7 In addition, as previously reported, we found that this regimen was associated with a very tolerable toxicity profile, with manageable cytopenias as the most common complication. Despite stabilization of disease and measurable response in up to 46% of patients (6 out of 13); only 4 patients (28%) are currently alive. Only 1 patient is in maintained remission after cyclo/topo alone; 2 of the remaining 3 survivors had further disease progression after cyclo/topo and responded to third-line therapy, and 1 patient is still on treatment with active disease. Thus, treatment with cyclo/topo seems to induce responses in a subset of patients, but rates of long-term remission remain low. Of note, 2 of our patients received daily oral sirolimus in addition to cyclo/topo at first relapse; these 2 patients had disease stabilization for 8 and 12 months, and no significant side effects were noted. Whether sirolimus contributed (9) *Patient received oral sirolimus during treatment with cyclo/topo. wPatient received only VDC initially. At relapse treated with cyclo/topo alternating with ifosfamide/etoposide, and received 8 cycles of each. zLocal control during or immediately after cyclo/topo salvage therapy. AWD indicates alive with disease; CR2, second remission; CR4, fourth remission; DOD, dead of disease; GTR, gross total resection; NA, not assessable; NED, no evidence of disease; PD, progressive disease; PR, partial response; SD, stable disease; XRT, radiation.
to this prolonged disease stabilization is unclear, but this combination may warrant further study in high-risk sarcomas, based on preclinical reports of synergism between cyclophosphamide and sirolimus in pediatric sarcomas. 22 The majority of disease sites in our reported series were local/regional recurrences. Of a total of 41 patients with Ewing sarcoma, recurrent disease occurred in 17, and 14 of those were included in this study. Of the 17 patients, 8 (47%) had local recurrences, and 1 (6%) had both local and metastatic disease. The rate of local versus distant recurrences differs among reported series. For example, in the review of 220 patients treated at St Jude Children's Research Hospital, 43% of recurrences were local/regional, and an additional 18% had both local and metastatic relapse. 23 In another series from Italy, local sites accounted for only 27% of recurrences, most of which were also associated with synchronous metastatic progression. 24 The small number of patients in our report precludes any definitive comparisons, because of potential biases due to individual patient risk features. For example, 7 of the 8 patients with local/regional recurrences in our series had tumor location at axial sites, 2 of the 3 patients with recurrent chest wall tumors had initial multiple pleural deposits, and the third had not undergone initial local control because of acute hepatitis C infection.
In our series, aggressive surgical local control was pursued in patients in whom the tumor was deemed resectable, and radiation was performed for positive margins when possible. A recent study showed that local control was associated with a better survival in relapsed Ewing sarcoma, 9 whereas a prior study showed that it had no prognostic significance. 11 Nine of our 14 patients had local control pursued. Patient outcome by local control is shown in Table 3 . Six patients achieved complete surgical resection, and 4 of those also received postoperative radiation therapy. The remaining 3 patients had unresectable tumors, and received radiation therapy as the only local control modality. Of the 6 patients who underwent complete tumor resection, 2 had pelvic site disease, and underwent internal hemipelvectomy. Both developed tumor recurrence at distant sites (multiple bone metastases). In contrast, 3 of the 4 patients currently alive had local recurrence at sites that allowed aggressive surgical local control, and they all received adjuvant radiation therapy. However, the short follow-up in 2 of the current survivors, and the small number of patients in our series, preclude making conclusions regarding the prognostic value of local control modality in salvage therapy.
Interestingly, the longest survivor in our series had disease that continued to show chemosensitivity despite multiple disseminated recurrences, and who continued to have durable responses to therapy after each recurrence. This patient had a late relapse (34 mo from diagnosis), and has achieved chemotherapy-induced remissions after a local recurrence (reported here), then a recurrence with brain metastases (treated with irinotecan/temodal and radiation therapy), and then a recurrence with disseminated bone marrow disease (treated with gemcitabine/docetaxel). He is now doing well with no evidence of disease, 9 years after initial salvage therapy and 12 years from initial diagnosis. This points to inherent biological differences among Ewing sarcoma tumors, and serves as an example that therapy may continue to be successful in some patients despite multiple recurrences.
Our results show that, in a homogenously treated patient population at a single institution, cyclo/topo could achieve measurable response and disease stabilization in a subset of patients with Ewing sarcoma at first relapse. However, the response was short-lived in the majority of patients. The lack of durability of response and the lowtoxicity profile, both warrant the future investigation of regimen that add other active agents to this chemotherapeutic backbone in relapsed disease. Such regimen may include irinotecan/temozolomide, which have shown activity in relapsed Ewing sarcoma, 13, 14 especially because the mechanism of tumor resistance to irinotecan seems to be different than that to topotecan 25 ; other possibilities could involve addition of targeted agents such as inhibitors of the mTOR and/or the insulin growth factor pathways. 21, 26, 27 
